2024 年至 2031 年下游加工市场规模（依最终用户、业务规模、生物分子类型和地区划分）

2024 年至 2031 年下游加工市场评估

受生物製药需求增加、慢性病发病率上升以及一次性技术日益普及等因素推动，下游加工市场预计将在未来几年大幅增长。据 Verified Market Research 分析师称，下游加工市场规模预计将从 2024 年的 299.3 亿美元增至 2024 年的 1,001.8 亿美元。

企业不断创新，提高效率和可扩展性，确保市场活力和竞争力。这将使市场从 2024 年到 2031 年的复合年增长率达到 16.30%。

下游加工市场定义/概述

下游加工是指生物製品生产后的重要步骤。这涉及从最初发现的复杂混合物中分离和纯化所需产品。这种混合物通常称为发酵液，可能含有细胞、废弃蛋白质、营养素和其他细胞产品。

下游加工对于从生物来源获取有价值的产品起着关键作用。它们用于纯化胰岛素和疫苗等生物製药、分离食品生产等工业过程所需的酵素以及从植物和微生物中提取药用天然产物。本质上，我们从细胞和生物体中提取原始输出物，并将其转化为纯净的功能性产品，以用于我们的健康和各种工业应用。

哪些因素推动下游加工厂需求激增？

生物製药（一种源自生物体或其细胞过程的药物）的需求不断增长，是下游加工的主要驱动力。生物製药比传统药物有几个优势，包括目标特异性高、副作用少、能够治疗复杂疾病。这促使了生物製药的开发和生产的激增，例如胰岛素、用于癌症治疗的单株抗体和基因治疗药物。因此，对高效、可扩展的下游加工技术来纯化和分离这些复杂分子的需求庞大。

此外，癌症、糖尿病和自体免疫疾病等慢性病的增加给全球医疗保健系统带来了巨大压力。这些慢性疾病通常需要长期治疗，而生物製药被证明是这场斗争中的强大武器。例如，生物製药可以透过调节血糖水平来帮助控製糖尿病，或比传统化疗药物更精确地瞄准癌细胞，最大限度地减少患者的副作用。随着全球人口不断老化以及慢性病发病率不断上升，对有效生物製药疗法的需求可能会相应增加，从而推动下游加工市场的发展。

哪些因素阻碍了下游加工市场的成长？

下游处理可能是一个非常昂贵的工作。特别是色谱系统和超滤设备需要大量的资本支出。此外，色谱树脂和过滤器等消耗品也会增加成本。此外，熟练的劳动力对于操作和维护下游加工设备以及确保製程效率至关重要。由于需要专业知识，很难获得合格的人员，而且他们的薪资对生产成本有很大影响。

此外，下游加工本质上很复杂，涉及针对要纯化的特定产品定制的多个步骤。必须仔细优化每个步骤以实现高产量并满足严格的纯度要求。这个优化过程非常耗时，并且需要色谱、过滤和蛋白质生物化学等领域的专业知识。下游加工的复杂性可能对中小型公司和首次进入生物製药製造领域的公司构成重大课题。我们可能没有内部专业知识或资源来开发和实施高效的精炼流程，这可能会阻碍我们在市场上有效竞争。

目录

第 1 章简介

• 市场定义
• 市场区隔
• 研究方法

第 2 章执行摘要

• 主要发现 市场概况
• 市场亮点

第三章 市场概览

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场限制
• 市场机会
• 波特五力分析

第 4 章 下游加工市场（依最终用户划分）

• 生物製药公司
• 合约製造组织 (CMO)
• 学术研究机构与研究机构

第五章 下游加工市场（依业务规模）

• 大规模下游加工
• 中等规模下游加工
• 小规模下游加工

6. 依生物分子类型划分的下游加工市场

• 蛋白质和抗体
• 疫苗
• 酶

第 7 章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 8 章 市场动态

• 市场推动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第 9 章 竞争格局

• 大型公司
• 市占率分析

第十章 公司简介

• Lonza Group
• Thermo Fisher Scientific Inc.
• Danaher Corporation（Pall Corporation）
• Sartorius Stedim Biotech S.A.
• Merck KGaA（Merck Millipore）
• 3M Company
• Eppendorf AG
• GE Healthcare
• Bio-Rad Laboratories, Inc.
• Boehringer Ingelheim

第 11 章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第 12 章附录

• 缩写列表
• 来源与参考文献

Downstream Processing Market Valuation - 2024-2031

The downstream processing market is expected to grow significantly in the coming years, driven by factors such as the increasing demand for biopharmaceuticals, the rising prevalence of chronic diseases, and the growing adoption of single-use technologies. According to the analyst from Verified Market Research, the downstream processing market is estimated to reach a valuation of 100.18 USD Billion over the forecast subjugating around 29.93 USD Billion valued in 2024.

Companies are continually innovating to improve efficiency and scalability, ensuring the market's dynamic and competitiveness. It enables the market to grow at aCAGR of 16.30% from 2024 to 2031.

Downstream Processing Market: Definition/ Overview

Downstream processing refers to the crucial steps taken after a biological product has been produced, typically through fermentation or cell culture. It's all about isolating and purifying the desired product from the complex mixture it's initially found in. This mixture, often called fermentation broth, can contain cells, unwanted proteins, nutrients, and other cellular byproducts.

Downstream processing plays a critical role in obtaining valuable products from biological sources. It's used to purify biopharmaceuticals like insulin and vaccines, isolate enzymes needed for industrial processes like food production, and extract natural products with medicinal properties from plants and microorganisms. In essence, it takes the raw output from cells or organisms and transforms it into the pure and functional products we rely on for health and various industrial applications.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What are the Factors that Surge the Demand for the Downstream Processing Market?

The rising demand for biopharmaceuticals, a category of drugs that are derived from living organisms or their cellular processes, is a major driver for downstream processing. Biopharmaceuticals offer several advantages over traditional medications, including higher target specificity, fewer side effects, and the ability to treat complex diseases. This has led to a surge in the development and production of biopharmaceuticals, such as insulin, monoclonal antibodies for cancer treatment, and gene therapies. As a result, the demand for efficient and scalable downstream processing techniques to purify and isolate these complex molecules has grown significantly.

Furthermore, the increasing prevalence of chronic diseases like cancer, diabetes, and autoimmune disorders places a significant burden on healthcare systems worldwide. These chronic conditions often require long-term treatment, and biopharmaceuticals are proving to be a valuable weapon in this fight. For instance, biopharmaceuticals can help manage diabetes by regulating blood sugar levels or target cancer cells more precisely than traditional chemotherapy drugs, minimizing side effects for patients. As the global population ages and the incidence of chronic diseases continues to rise, the demand for effective biopharmaceutical treatments will correspondingly increase, propelling the downstream processing market forward.

What Factors Hinder the Growth of the Downstream Processing Market?

Downstream processing can be a very expensive endeavor. The cost of equipment can be significant, especially for chromatography systems and ultrafiltration units. Consumables, such as chromatography resins and filters, also add to the bottom line. Furthermore, skilled labor is essential for operating and maintaining downstream processing equipment and ensuring process efficiency. The specialization required can make it challenging to find qualified personnel, and their salaries can contribute significantly to production costs.

Furthermore, Downstream processing is inherently complex, involving a multitude of steps tailored to the specific product being purified. Each step needs to be carefully optimized to achieve high yields and meet stringent purity requirements. This optimization process can be time-consuming and requires specialized expertise in areas like chromatography, filtration, and protein biochemistry. The complexity of downstream processing can pose significant challenges for smaller companies or those venturing into biopharmaceutical production for the first time. They may lack the in-house expertise or resources to develop and implement efficient purification processes, hindering their ability to compete effectively in the market.

Category-Wise Acumens

How Does the Increasing Demand for Biopharmaceutical Companies Contribute the Market Growth?

According to VMR analysis, the biopharmaceutical companies segment is estimated to hold the largest market share during the forecast period. Biopharmaceutical companies are the primary producers of drugs, vaccines, and other biopharmaceuticals. They require robust downstream processing capabilities to handle large-scale production volumes and ensure consistent product quality. Academic labs and research institutes typically work with smaller quantities for research purposes and may not require such extensive downstream processing infrastructure.

Furthermore, Biopharmaceutical companies are constantly striving to improve downstream processing efficiency and scalability. This is crucial for keeping production costs down and meeting growing market demands. Contract Manufacturing Organizations (CMOs), while offering downstream processing services, cater to a wider range of clients with varying needs. Biopharmaceutical companies often have the resources to invest in advanced, scalable downstream processing technologies, giving them an edge.

How does large-scale downstream processing Propel the Growth of the Downstream Processing Market?

The large-scale downstream processing segment is estimated to dominate the Downstream Processing market during the forecast period driven by the surge in demand for biopharmaceuticals, particularly for established drugs and therapies, which necessitates large-scale production to meet market needs. Large-scale downstream processing allows biopharmaceutical companies to achieve higher production volumes efficiently.

Furthermore, Large-scale operations benefit from economies of scale in several ways. Bulk purchasing of raw materials and consumables for downstream processing can lead to lower costs per unit. Additionally, large-scale facilities can potentially streamline processes and optimize resource utilization, further enhancing efficiency. For example, a large-scale facility might implement automated equipment and continuous processing techniques, which can reduce labor costs and improve throughput compared to smaller-scale batch processing. large facilities can leverage their buying power to negotiate better deals with suppliers of chromatography resins, filters, and other essential materials.

Country/Region-wise Acumens

How does Heightened Awareness of the Downstream Processing market Influence Growth in North America?

According to VMR analysts, North America is estimated to dominate the Downstream Processing market during the forecast period. North America boasts a well-established and strong pharmaceutical and biopharmaceutical industry. This translates to a high demand for downstream processing capabilities to support the production of various biopharmaceuticals.

North America has a well-developed healthcare infrastructure with stringent regulatory frameworks for biopharmaceutical production. This focus on quality necessitates advanced downstream processing methods to ensure product safety and efficacy.

Furthermore, Governments in North America, recognizing the potential of biopharmaceuticals to improve public health and drive economic growth, often provide significant funding and support for research and development in biopharmaceutical technologies. This financial backing fuels innovation in downstream processing techniques, encouraging the development of more efficient, scalable, and cost-effective methods for purifying biopharmaceuticals. Additionally, government grants and tax incentives can stimulate private sector investment in R&D, further accelerating advancements in downstream processing technologies. This strong focus on research fosters a collaborative environment where universities, research institutions, and biopharmaceutical companies can work together to develop next-generation downstream processing solutions.

What Factors Contribute to the Potential Opportunities in the Asia Pacific Region?

The Asia Pacific region is estimated to exhibit the highest growth within the Downstream Processing Market during the forecast period. The Asia-Pacific region is home to a vast and growing patient population. This, coupled with a rising middle class with more disposable income for healthcare, creates a significant market for biopharmaceuticals. This translates to a need for expanded downstream processing facilities to meet the anticipated demand. Additionally, As economies in the region flourish, governments are investing heavily in healthcare infrastructure and biopharmaceutical research. This surge in activity creates a strong demand for downstream processing capabilities to support large-scale biopharmaceutical production.

Furthermore, There's a growing emphasis on research and development (R&D) in the Asia-Pacific biopharmaceutical sector. This focus on innovation fosters collaboration between universities, research institutions, and biopharmaceutical companies. This collaborative environment can accelerate advancements in downstream processing technologies, leading to the development of more efficient, scalable, and cost-effective purification methods. Additionally, Regulatory frameworks for biopharmaceutical production in the Asia-Pacific region are becoming more streamlined and harmonized. This can ease the process for companies looking to establish downstream processing facilities in the region.

Competitive Landscape

The downstream processing market is a competitive landscape characterized by a dynamic interplay between established industry leaders and emerging companies with innovative technologies. Well-entrenched players leverage their vast experience, extensive product portfolios, and global reach to maintain a strong market presence.

Some of the prominent players operating in the Downstream Processing Market include:

Lonza Group

Thermo Fisher Scientific Inc.

Danaher Corporation (Pall Corporation)

Sartorius Stedim Biotech S.A.

Merck KGaA (Merck Millipore)

3M Company

Eppendorf AG

GE Healthcare

Bio-Rad Laboratories, Inc.

Boehringer Ingelheim

Latest Developments

In December 2024, Lonza Group partnered with a leading biotechnology company to develop and manufacture a novel gene therapy for a rare genetic disorder. Lonza's expertise in downstream processing will be crucial in purifying and isolating the large quantities of viral vectors needed for this gene therapy treatment. This collaboration highlights the growing importance of downstream processing in bringing innovative biopharmaceutical therapies to patients

In 2024, Thermo Fisher Scientific launched a new chromatography resin specifically designed for high-throughput protein purification. This innovative resin boasts a unique ligand chemistry that offers superior binding capacity and faster purification times for a wide range of protein targets. This can significantly improve the efficiency of downstream processing workflows, especially for biopharmaceutical companies working on large-scale production of protein-based drugs or therapeutics. The new resin is also designed to be compatible with high-flow chromatography systems, further accelerating protein purification processes.

In 2024, Danaher Corporation (Pall Corporation) introduced a new generation of single-use filters for improved performance and scalability in downstream processing.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Downstream Processing Market, By Final User

• Biopharmaceutical Companies
• Contract Manufacturing Organisations (CMOs)
• Academic labs and research institutes

5. Downstream Processing Market, By Operational Scale

• Large-Scale Downstream Processing
• Medium-Scale Downstream Processing
• Small-Scale Downstream Processing

6. Downstream Processing Market, By Biomolecule Type

• Proteins and Antibodies
• Vaccines
• Enzymes

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Lonza Group
• Thermo Fisher Scientific Inc.
• Danaher Corporation (Pall Corporation)
• Sartorius Stedim Biotech S.A.
• Merck KGaA (Merck Millipore)
• 3M Company
• Eppendorf AG
• GE Healthcare
• Bio-Rad Laboratories, Inc.
• Boehringer Ingelheim

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References